Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Paritaprevir→

Paritaprevir PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1216941-48-8
PubChem CID
45110509
Molecular formula
C40H43N7O7S
Molecular weight
765.9 g/mol
Drug class
Hepatitis C virus (HCV) NS3/4A serine protease inhibitordirect-acting antiviral
Mechanism of action
Reversibly binds the active centre of the HCV NS3/4A protease and prevents protease-mediated cleavage of the viral polyprotein, disrupting maturation of viral proteins needed for replication. It is used in combination regimens; ritonavir increases paritaprevir exposure through CYP3A4 inhibition.
Indications / reported uses
  • Used only as part of labelled combination regimens for chronic hepatitis C, such as ombitasvir/paritaprevir/ritonavir with or without dasabuvir; indication and availability are regimen- and jurisdiction-specific.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ombitasvir-paritaprevir-ritonavir · https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax

Identification source: PubChem record (CID 45110509). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Hepatitis C virus (HCV) NS3/4A serine protease inhibitor; direct-acting antiviral

Mechanism of action

Reversibly binds the active centre of the HCV NS3/4A protease and prevents protease-mediated cleavage of the viral polyprotein, disrupting maturation of viral proteins needed for replication. It is used in combination regimens; ritonavir increases paritaprevir exposure through CYP3A4 inhibition.

General use cases

  • Used only as part of labelled combination regimens for chronic hepatitis C, such as ombitasvir/paritaprevir/ritonavir with or without dasabuvir; indication and availability are regimen- and jurisdiction-specific.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Paritaprevir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Paritaprevir Permitted Daily Exposure (PDE) report (the Paritaprevir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Paritaprevir Occupational Exposure Limit (OEL) report (the Paritaprevir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.